Empagliflozin

Hypoglycaemic excluding Insulin · Reversible inhibitor of sodium-glucose co-transporter 2 (SGLT2)

Indications

Type 2 diabetes inadequately controlled by diet and exercise; as monotherapy when metformin is not tolerated; or with other hypoglycaemic including insulin, when these alone are inadequate.

Dosage

Adults: 10 mg once daily, increase to 25 mg once daily if necessary. In combination therapy consider lower dose of insulin/sulfonylurea. Children: Not recommended.

Adverse Effects

Genital infection, UTI, increased urination, pruritus. In combination therapy hypoglycaemia.

Risk Factor (Pregnancy/Lactation)

Pregnancy: Contraindicated in pregnancy. Lactation: Contraindicated or not recommended. Contraindications: Diabetic ketoacidosis, Elderly (> 85 years), severe hepatic or renal impairment (eGFR <45ml/min/1.73msq). Precautions: Moderate renal impairment. Monitor renal function before starting treatment and at least annually thereafter. Monitor volume status and electrolyte in patient at risk of volume depletion. Risk of diabetic ketoacidosis; warn patients to report symptoms immediately and test ketone level if occur. Pyelonephritis, urosepsis. Patients will test positive for glycosuria. Cardiovascular disease, history of tension. Elderly >75 years.

Interactions

Diuretics, antihypertensive, agents that affect renal function, UGT enzyme inducers.

Advice to Patient

Take with meals.

Pharmacokinetics

Metabolism: Hepatic. Half-life elimination: 12.4 hrs. Time to peak: 1.5 hrs. Excretion: Urine (54.4%). Faeces (41.2%).

Brands with this active ingredient

• Empanext

Compiled by Healify Pharmacy from published drug references. How we compile it →

Always consult a pharmacist or doctor.